DR-TB Drugs Under the Microscope, 2nd Edition
This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.
Also, as the R&D pipeline prepares to deliver the first new compounds for TB in close to half a century, the report provides an initial assessment of the approaches to be taken in order to radically transform our ability to respond to this plague.
Additional publications in the DR-TB Drugs Under the Microscope report series are available here.
Learn more about MSF’s work to improve access to lifesaving TB treatment.